Latest news with #MyriadGenetics
Yahoo
3 days ago
- Business
- Yahoo
TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN)
Myriad Genetics, Inc. (NASDAQ:MYGN) is one of the . On August 5, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics, Inc. (NASDAQ:MYGN) with a $6 price target. The rating follows the company's fiscal second quarter 2025 earnings release, where the company posted a strong quarter after a weaker first quarter for 2025. Myriad Genetics, Inc. (NASDAQ:MYGN) posted revenue of $213.10 million, reflecting around 1% year-over-year growth and ahead of expectations by $10.8 million. The EPS of $0.05 also exceeded expectations by $0.06. A medical professional in a laboratory analyzing the outcomes of a molecular diagnostic test. Brennan noted that this was mainly due to a solid performance in Hereditary Cancer Testing and GeneSight. However, he highlighted that the Prenatal segment remains weak, and the outlook for the second half of 2025 hints at a possible decline in year-over-year growth. The company also faces challenges from the loss of a GeneSight contract and issues with electronic medical records affecting volumes, thereby resulting in a cautious rating from the analyst. Myriad Genetics, Inc. (NASDAQ:MYGN) is a genetic testing and precision medicine company that develops genetic tests to help assess disease risk and guide treatment decisions. While we acknowledge the potential of MYGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
06-08-2025
- Business
- Yahoo
Why Is Myriad Genetics (MYGN) Stock Soaring Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 36.4% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year revenue forecast. The genetic testing firm announced revenue of $213.1 million, which sailed past analyst estimates of around $202 million. It also posted an adjusted profit of $0.05 per share, a significant turnaround from the minor loss that experts had predicted. A key driver for this outperformance was the company's hereditary cancer testing business, which grew 9% compared to the previous year. Bolstered by this momentum, Myriad Genetics lifted its full-year revenue guidance to a range of $818 million to $828 million and secured a new $200 million credit facility to fund its growth. Is now the time to buy Myriad Genetics? Access our full analysis report here, it's free. What Is The Market Telling Us Myriad Genetics's shares are extremely volatile and have had 35 moves greater than 5% over the last year. But moves this big are rare even for Myriad Genetics and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 8 days ago when the stock dropped 3.8% on the news that weakness in the healthcare sector became pronounced following a poor sales report from a key competitor. The negative sentiment was partly fueled by health insurance giant UnitedHealth Group, which reported a miss on its second-quarter earnings and issued a profit warning, casting a pall over the entire sector. More directly, NeoGenomics, a company also operating in the cancer diagnostics space, reported that it had missed its second-quarter sales targets. This news, which sent NeoGenomics' stock down significantly, suggested a potentially more challenging market environment for companies involved in oncology diagnostics, a core business for Myriad Genetics. Myriad Genetics is down 58.8% since the beginning of the year, and at $5.56 per share, it is trading 80.5% below its 52-week high of $28.60 from September 2024. Investors who bought $1,000 worth of Myriad Genetics's shares 5 years ago would now be looking at an investment worth $449.06. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Sign in to access your portfolio
Yahoo
05-08-2025
- Business
- Yahoo
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street's expectations in Q2 CY2025, but sales were flat year on year at $213.1 million. The company's full-year revenue guidance of $823 million at the midpoint came in 1.5% above analysts' estimates. Its non-GAAP profit of $0.05 per share was significantly above analysts' consensus estimates. Is now the time to buy Myriad Genetics? Find out in our full research report. Myriad Genetics (MYGN) Q2 CY2025 Highlights: Revenue: $213.1 million vs analyst estimates of $202 million (flat year on year, 5.5% beat) Adjusted EPS: $0.05 vs analyst estimates of -$0.01 (significant beat) Adjusted EBITDA: $14.5 million vs analyst estimates of $4.75 million (6.8% margin, significant beat) The company slightly lifted its revenue guidance for the full year to $823 million at the midpoint from $815 million EBITDA guidance for the full year is $30 million at the midpoint, above analyst estimates of $20.53 million Operating Margin: -154%, down from -17.3% in the same quarter last year Free Cash Flow was -$20.5 million compared to -$2.6 million in the same quarter last year Market Capitalization: $366.9 million "We delivered solid second-quarter results, driven by continued strength in hereditary cancer testing in oncology, improving momentum in hereditary cancer testing for unaffected individuals, and favorable pricing trends supported by mix and our ongoing efforts to expand payer coverage. Our disciplined approach to expense management contributed to our improved profitability while we continued to invest in strategic drivers to enable long-term growth," said Sam Raha, President and CEO, of Myriad Genetics. Company Overview Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Revenue Growth A company's long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Myriad Genetics grew its sales at a mediocre 5.5% compounded annual growth rate. This was below our standard for the healthcare sector and is a poor baseline for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Myriad Genetics's annualized revenue growth of 9.2% over the last two years is above its five-year trend, suggesting some bright spots. This quarter, Myriad Genetics's $213.1 million of revenue was flat year on year but beat Wall Street's estimates by 5.5%. Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and indicates its products and services will see some demand headwinds. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Adjusted Operating Margin Although Myriad Genetics was profitable this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average adjusted operating margin of negative 1.3% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. On the plus side, Myriad Genetics's adjusted operating margin rose by 4.2 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company's margin has increased by 11.2 percentage points on a two-year basis. In Q2, Myriad Genetics generated an adjusted operating margin profit margin of 4%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Myriad Genetics's full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it's at a critical moment in its life. In Q2, Myriad Genetics reported adjusted EPS at $0.05, in line with the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Myriad Genetics to perform poorly. Analysts forecast its full-year EPS of $0.11 will hit $0.09. Key Takeaways from Myriad Genetics's Q2 Results This was a beat and raise quarter. We were impressed by how significantly Myriad Genetics blew past analysts' revenue, EBITDA, and EPS expectations this quarter. We were also excited its full-year revenue guidance was raised and full-year adjusted EBITDA guidance was ahead of expectations. Zooming out, we think this quarter featured some very important positives. The stock traded up 30.6% to $5.04 immediately after reporting. Myriad Genetics put up rock-solid earnings, but one quarter doesn't necessarily make the stock a buy. Let's see if this is a good investment. We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
29-07-2025
- Business
- Yahoo
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the second quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at following the call. About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit Investor Contact Matt Scalo (801) 584-3532 IR@ Media Contact Kate Schraml(224) 875-4493PR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
3 Cash-Burning Stocks Facing Headwinds
Rapid spending isn't always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. Negative cash flow can lead to trouble, but StockStory helps you identify the businesses that stand a chance of making it through. That said, here are three cash-burning companies to avoid and some better opportunities instead. Trailing 12-Month Free Cash Flow Margin: -2.1% Cooling America's first indoor ice rink in the 19th century, Enviri (NYSE:NVRI) offers steel and waste handling services. Why Should You Sell NVRI? Sales trends were unexciting over the last two years as its 7.1% annual growth was below the typical industrials company Cash-burning history makes us doubt the long-term viability of its business model Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders Enviri's stock price of $8.15 implies a valuation ratio of 2.6x forward EV-to-EBITDA. If you're considering NVRI for your portfolio, see our FREE research report to learn more. Trailing 12-Month Free Cash Flow Margin: -2.9% Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Why Do We Think MYGN Will Underperform? Annual revenue growth of 1.8% over the last five years was below our standards for the healthcare sector Earnings per share fell by 29.7% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable Negative returns on capital show that some of its growth strategies have backfired, and its shrinking returns suggest its past profit sources are losing steam Myriad Genetics is trading at $4.09 per share, or 32.5x forward P/E. To fully understand why you should be careful with MYGN, check out our full research report (it's free). Trailing 12-Month Free Cash Flow Margin: -1.8% Following its 2023 acquisition of DISH Network, EchoStar (NASDAQ:SATS) provides satellite communications, pay-TV services, wireless networks, and broadband solutions across consumer and enterprise markets. Why Are We Cautious About SATS? Incremental sales over the last five years were much less profitable as its earnings per share fell by 11.5% annually while its revenue grew 6.8 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders At $20.50 per share, EchoStar trades at 3.6x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including SATS in your portfolio, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
